ERBB2 and breast cancer: Here, we describe our experience with the use of dual anti-HER2 monoclonal blockade with Trastuzumab and Pertuzumab in combination with Paclitaxel in severe hepatic and pulmonary dysfunction secondary to visceral metastasis of a recurrent HER2-positive breast cancer patient.